257 related articles for article (PubMed ID: 94893)
1. [Effect of fibrin-fibrinogenolysis on the determination of the fibrinogen content and fibrin-fibrinogen degradation products (FDP) by means of the fibrin polymerization time (FPT test)].
Vorlová Z; Dyr IE
Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):967-70. PubMed ID: 94893
[No Abstract] [Full Text] [Related]
2. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
Dyr JE; Cajthamlová H; Suttnar J
Cas Lek Cesk; 1990 Oct; 129(43):1349-51. PubMed ID: 2249231
[TBL] [Abstract][Full Text] [Related]
5. [Studies on the fragments of FDP in 3 patients with DIC associated with acute promyelocytic leukemia].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
Rinsho Byori; 1993 Jun; 41(6):719-25. PubMed ID: 8361040
[TBL] [Abstract][Full Text] [Related]
6. [Immunoenzyme determination of fibrin-fibrinogen degradation product levels in acute myocardial infarct patients].
Grinshteĭn IA; Ignashenkova GV; Kitaev MI
Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1987; 10(1):18-21. PubMed ID: 3300697
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen degradation products in plasma following induced hyperfibrinolysis.
Chek JB; Panchenko NI
East Afr Med J; 2000 Apr; 77(4):217-20. PubMed ID: 12858907
[TBL] [Abstract][Full Text] [Related]
8. [Fibrin and fibrinogen degradation products in head- and neck-tumors (author's transl)].
Wilmes EH; Hochstrasser K
Laryngol Rhinol Otol (Stuttg); 1978 Dec; 57(12):1083-6. PubMed ID: 732487
[TBL] [Abstract][Full Text] [Related]
9. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma.
Koppert PW; Kuipers W; Hoegee-de Nobel B; Brommer EJ; Koopman J; Nieuwenhuizen W
Thromb Haemost; 1987 Feb; 57(1):25-8. PubMed ID: 2438796
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
Lychev VG; Momot AP; Cherkashin GV
Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
Feddersen C
Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
[No Abstract] [Full Text] [Related]
12. Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays.
Arnesen H
J Oslo City Hosp; 1977 Jun; 27(6):69-80. PubMed ID: 142131
[No Abstract] [Full Text] [Related]
13. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
Rozenfel'd MA; Leonova VB; Khavkina LS
Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
[TBL] [Abstract][Full Text] [Related]
14. [Comparative fibrinogen determination by artificial in vitro fibrinogen lysis with regard to fibrinogen split products].
Kätzel R; Brunner HP; Bohr A
Z Med Lab Diagn; 1981; 22(3):138-43. PubMed ID: 7293326
[No Abstract] [Full Text] [Related]
15. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
Lipinski B; Gurewich V; Hyde E
Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
[No Abstract] [Full Text] [Related]
16. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
[TBL] [Abstract][Full Text] [Related]
17. [Relation between fibrin/fibrinogen degradation products in malignant fluids and the fibrinolytic activity of the peritoneum].
Takahashi M; Yoshida K; Kano K; Machida T; Nakamura Y; Miura Y; Miura N; Kanno S
Gan No Rinsho; 1986 Dec; 32(15):1945-9. PubMed ID: 3806965
[TBL] [Abstract][Full Text] [Related]
18. [Critical evaluation of new methods for studying fibrin degradation products].
Prisco D
Recenti Prog Med; 1989 May; 80(5):263-7. PubMed ID: 2669062
[TBL] [Abstract][Full Text] [Related]
19. [Differentiation between fibrin degradation products and fibrinogen degradation products by using newly developed ELISAs].
Isogai N; Yamagishi T; Kaku M; Matsumoto K; Yamamoto Y; Kuroso K; Arai M; Yorifuji H; Fukutake K; Fujimaki M
Rinsho Byori; 1991 Jul; 39(7):753-7. PubMed ID: 1920869
[TBL] [Abstract][Full Text] [Related]
20. Reactivity of D-dimer assays with the fibrinogen--fibrin split products generated by thrombolytic agents.
Amiral J; Minard F; Plassart V; Vissac AM; Chambrette B
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):525-30. PubMed ID: 2133230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
